GW280264X is the mixed ADAM10/TACE (ADAM17) metalloproteinases inhibitor. GW280264X potently blocks TACE (ADAM17) and ADAM10 with IC 50 s of 8.0 nM and 11.5 nM, respectively ADAM10 and 17 modulate the immunogenicity of glioblastoma-initiating cells .
In Vitro
The proliferation of GS-7 cells was significantly reduced upon treatment with GW280264X or ADAM10/17 co-knockdown. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Glioblastoma-initiating cells (GIC) GS-7 cells Concentration: 0.1, 1, and 3 µM Incubation Time: 48 hours Result: Proliferation of GIC is inhibited through inhibition of ADAM10 and ADAM17.
In Vivo
Pharmacological inhibition of ADAM10 and ADAM17 improves functional recovery after spinal cord injury (SCI). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 miceDosage: 100 µg/kg Administration: I.p. injected; every day for one week starting 4 h post-surgery Result: Showed significantly improved functional recovery compared to the control group.